Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 4/20 | 0.70 |
| ▸ | BRPF1 | P55201 | 9/20 | 0.46 |
| ▸ | BRD1 | O95696 | 5/20 | 0.46 |
| ▸ | BRPF3 | Q9ULD4 | 5/20 | 0.46 |
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | AR | P10275 | 3/20 | 0.45 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.45 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.45 |
| ▸ | ALPL | P05186 | 2/20 | 0.43 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1941882 | 0.87 | TRPV4 (0.57) | TRPV4ARALPLPTGES2 | |
| SCHEMBL6559390 | 0.85 | TRPV4 (0.62) | TRPV4BRPF1BRD1BRPF3BRD9 | |
| SCHEMBL10034994 | 0.83 | PKM (0.53) | TRPV4BRPF1BRD1BRPF3BRD9 | |
| SCHEMBL29420303 | 0.83 | TRPV4 (1.00) | TRPV4BRPF1 | |
| SCHEMBL23140910 | 0.83 | TRPV4 (1.00) | TRPV4BRPF1 | |
| SCHEMBL20743622 | 0.81 | BRPF1 (0.52) | TRPV4BRPF1BRD1BRPF3BRD9 | |
| SCHEMBL1082080 | 0.80 | TRPV4 (0.61) | TRPV4 | |
| SCHEMBL1798881 | 0.80 | EPAS1 (0.49) | TRPV4BRPF1BRD1BRPF3BRD9 | |
| SCHEMBL7280551 | 0.78 | ACLY (0.53) | TRPV4ALPL | |
| SCHEMBL20003543 | 0.78 | TRPV4 (0.63) | TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025136811-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | IDEAYA BIOSCIENCES, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250122182-A1 | MYST Inhibitors | Isosterix, Inc. | 2025-04-17 | — | — | US | disclosed |
| US-10889555-B2 | Sulfonamide compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-12 | — | — | US | disclosed |
| US-20200405697-A1 | Antitumor Agent | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-31 | — | — | US | disclosed |
| US-20200399235-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-24 | — | — | US | disclosed |
| EP-3718545-A1 | ANTITUMOR AGENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-10-07 | — | — | EP | disclosed |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-05-21 | — | — | US | disclosed |
| EP-3466934-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017209155-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | 大鵬薬品工業株式会社 | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399235-A1 | Sulfonamide Compound or Salt Thereof | RNASEH1, SNRPA1, RRM2 | TRPV4 1831/4885BRPF1 3660/4885BRD1 1387/4885 |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | RNASEH1, SNRPA1, RRM2 | TRPV4 1831/4885BRPF1 3660/4885BRD1 1387/4885 |
| US-10889555-B2 | Sulfonamide compound or salt thereof | RNASEH1, SNRPA1, RRM2 | TRPV4 1831/4885BRPF1 3660/4885BRD1 1387/4885 |
| US-20250122182-A1 | MYST Inhibitors | MNAT1, SUGT1, ACAT2 | TRPV4 4752/4885BRPF1 1486/4885BRD1 163/4885 |
| US-20200405697-A1 | Antitumor Agent | HNRNPR, RRM2, RRM2B | TRPV4 3337/4885BRPF1 3148/4885BRD1 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.